Christian Sire

Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial

Jean Bourhis, Christian Sire, P. Gräff et al. · The Lancet Oncology · 2012 · 382 citations

Medicine, Oncology, Radiation Oncology +11

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial

Lionnel Geoffrois, Laurent Martin, D. De Raucourt et al. · Journal of Clinical Oncology · 2018 · 148 citations

Medicine, Oncology, Radiation Oncology +15

Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study

Xu-Shan Sun, Yungan Tao, Christophe Le Tourneau et al. · The Lancet Oncology · 2020 · 130 citations

Medicine, Oncology, Radiation Oncology +11

Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)

Yungan Tao, Anne Aupérin, Xu-Shan Sun et al. · European Journal of Cancer · 2020 · 97 citations · Full text

Medicine, Oncology, Radiation Oncology +11